stella
beta
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients — Stella
Recruiting
Back to Spinal Muscular Atrophy Type 3 trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
China
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality
View full record on ClinicalTrials.gov